Declining sales of Prevnar have urged Pfizer to seek compensation elsewhere, including a vaccine against Group B streptococcus.
BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.
Scientific progress is leading to effective—but sometimes expensive—new treatments. Learn how value-based contracting could be the solution to pay for these…
Florida lawmakers are urging the Army to pump the brakes on its exclusive vaccine license to Sanofi.
Scientists at the University of Maryland, hoping to fill the hepatitis vaccine void, have secured funding from the NIH to work on a new candidate.
Norwegian biotech Targovax has raised about €21 million in a private placement.
A new U.S. study shows that Merck's Ebola vaccine rVSV-ZEBOV offers protection that can last for at least a year.
Merck & Co. may not be number one with a bullet in vaccines, but CEO Ken Frazier says the unit shouldn't be underestimated.
The Radboud University Medical Center in the Netherlands, the Instituto de Medicina Molecular Lisboa in Portugal, and PATH are collaborating on a human trial…
Bristol-Myers Squibb's Opdivo is in more vaccine combo studies than its PD-1/PD-L1 rivals, according to a new report.
Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.